Nivolumab improves survival of kidney cancer patients at three years

Updated results from the phase 3 CheckMate-025 study, presented at the 16th International Kidney Cancer Symposium in Miami, USA last week, show a three-year survival benefit of nivolumab (Opdivo) over everolimus (Afinitor) in advanced renal cell carcinoma (RCC). The risk of death was also reduced by 26% for the people taking nivolumab.

CheckMate-025 evaluated previously treated advanced RCC patients treated with nivolumab versus everolimus. The data are the first of any anti-programmed death-1 (PD-1) agent to demonstrate durable survival at three years in previously treated RCC. Nivolumab was well tolerated and the data showed a safety profile consistent with the two-year results.

Median overall survival (OS) for nivolumab was 25.8 months compared to 19.7 months with everolimus. The three-year OS rate was 39% for nivolumab and 30% for everolimus.

“The updated results of CheckMate-025 reinforce the overall survival benefit and safety profile of Opdivo and provide further support for this therapeutic option as a standard of care for patients with previously treated advanced renal cell carcinoma,” said Dr Padmanee Sharma, scientific director, Immunotherapy Platform, MD Anderson Cancer Center, Texas, USA.

Read more here

Share this Post!

Related post